Seastar Medical Hldg Corp (ICU) Stock Price, Quote & News

Company Profile

SeaStar Medical Holding Corporation, a commercial-stage medical device company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI)...

Industry: Biotechnology

Sector: Healthcare

Phone: 844 427 8100

Website: seastarmedical.com

Address:

3513 Brighton Boulevard, Suite 410, Denver, United States

dnwnwntlqkffjadk Nov. 15 at 3:06 AM

$ICU This company isn't experiencing transitional difficulties. If their product were as superior as they claim and the market demanded it, sales would have already been positive. They only talk about getting approval for the adult version, and even though the FDA gave them a fast-track license to sell the children's version, no hospital would buy this "miracle device." So what difference does an adult version make? Selling two more devices a year? That's not even enough to cover Eric's desserts.

0 · Reply

dnwnwntlqkffjadk Nov. 15 at 3:01 AM

$ICU Despite the fact that everyone who invested for more than three years suffered losses of over 99%, endless lies, failed clinical trials, and dilution, there are those who continue to praise and defend this scam. The daily "additional purchase" figures they post are far greater than the total trading volume for the day. Anyone who praises a stock that loses 99% of its value is either out of their minds or harbors malicious intent.

0 · Reply

Bobbypogo Nov. 15 at 2:21 AM

$ICU The only thing that makes sense is Fast Track K Chung has a lot of connections and is highly regarded in his field

0 · Reply

Tjcmd Nov. 15 at 2:16 AM

$ICU RS is not necessarily a death sentence…look at what happened with CDTX today! Merk buying for $221.50!!!

1 · Reply

holn1 Nov. 15 at 12:47 AM

$ICU hope everyone has a great weekend. We're cooked!

0 · Reply

Aznwactrackstar Nov. 15 at 12:39 AM

$ICU this is seriously so depressing. What a close.

1 · Reply

windswept Nov. 15 at 12:08 AM

$ICU https://x.com/drpatsoonshiong/status/1989363831882268971?s=46&t=XftF5LoFh8RT7vWzELGP1g

1 · Reply

local42r Nov. 14 at 10:55 PM

$ICU If, I mean if seastar made a proposal to the FDA to lift the restrictions, And the FDA gave them a green light, it would shoot the sp way beyond 1 dollars. Nice dream but possible.

0 · Reply

Jafo333isme Nov. 14 at 10:27 PM

$ICU I probably don't need to tell you this because none 1 2 3 has been incessantly posting about it. But $IVVD was a good play this morning - of course I was already bought in before the run which is key, but it's made for some pretty nice swing trades over the last couple of weeks. Me? I'm long on both. I'm not going to Short a company that's barely scraping by to survive and is trying to help usher one of the most useful pieces of medical technology this century to the world. Is Eric a shitty CEO?? I can't say he's the best CEO but also I've never attempted to run a biotech company myself 🤷‍♀️

0 · Reply

techjerk Nov. 14 at 9:58 PM

$ICU Phuck stocks Cheers https://www.facebook.com/100064755394296/videos/2589531644750692/

0 · Reply

SeaStar Medical Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 5, 2025, 10:03 AM EST - 9 days ago

SeaStar Medical to Report Third Quarter Financial Results on November 13, 2025

Sep 29, 2025, 8:36 AM EDT - 6 weeks ago

SeaStar Medical Reports Positive Early Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) at the 5th International Symposium on Acute Kidney Injury in Children

Sep 24, 2025, 4:22 PM EDT - 7 weeks ago

SeaStar Medical Reports DSMB Recommendation to Continue the NEUTRALIZE-AKI Pivotal Trial in Adult Acute Kidney Injury

Sep 23, 2025, 8:23 AM EDT - 7 weeks ago

SeaStar Medical to Present Early SAVE Registry Data of QUELIMMUNE in Pediatric Acute Kidney Injury at the 5th International Symposium on Acute Kidney Injury in Children

Sep 4, 2025, 6:13 PM EDT - 2 months ago

SeaStar Medical to Participate in the HC Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 8:22 AM EDT - 2 months ago

SeaStar Medical Announces Newly Published QUELIMMUNE Health Economic Study Projecting Significantly Reduced Health Care Costs in the Treatment of Pediatric AKI due to Estimated Shorter Hospital Stays and Increased Survival

Aug 13, 2025, 4:05 PM EDT - 3 months ago

SeaStar Medical Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 7, 2025, 10:00 AM EDT - 3 months ago

SeaStar Medical to Report Second Quarter Financial Results on August 13, 2025

Aug 6, 2025, 8:33 AM EDT - 3 months ago

SeaStar Medical Reaches New Enrollment Milestone in NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury (AKI)

Jul 31, 2025, 3:01 PM EDT - 3 months ago

SeaStar Medical Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jul 22, 2025, 8:20 AM EDT - 4 months ago

SeaStar Medical Reports Positive Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) from the First 20 SAVE Surveillance Registry Patients

Jul 16, 2025, 8:45 AM EDT - 4 months ago

SeaStar Medical Grows Customer Base and Expands QUELIMMUNE Surveillance Registry

Jul 10, 2025, 3:29 PM EDT - 4 months ago

SeaStar Medical Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jul 8, 2025, 8:05 AM EDT - 4 months ago

SeaStar Medical Expands QUELIMMUNE Adoption for Critically Ill Pediatric Patients with Acute Kidney Injury (AKI)

Jul 2, 2025, 4:25 PM EDT - 4 months ago

SeaStar Medical Announces Positive Nasdaq Listing Determination

Jun 25, 2025, 8:05 AM EDT - 5 months ago

SeaStar Medical Reports Update on Nasdaq Listing Status

Jun 24, 2025, 9:05 AM EDT - 5 months ago

SeaStar Medical Announces Two Feature Stories on QUELIMMUNE Adoption and Patient Testimonial of Life-Saving Therapy

Jun 20, 2025, 12:10 PM EDT - 5 months ago

SeaStar Medical Announces Pricing of Up to $8 Million Public Offering

Jun 11, 2025, 8:25 AM EDT - 5 months ago

AREVA Institute and SeaStar Medical Announce DoD Award of Prestigious Military Grant to AREVA Institute to Evaluate SeaStar Medical's SCD Therapy to Advance Breakthrough Burn and Sepsis Research

May 28, 2025, 8:05 AM EDT - 6 months ago

SeaStar Medical Announces CMS Coverage for Medicare and Medicaid Eligible Patients with Cardiorenal Syndrome Awaiting LVAD in Investigational Trial of SCD Therapy

May 14, 2025, 9:49 PM EDT - 6 months ago

SeaStar Medical Holding Corporation (ICU) Q1 2025 Earnings Call Transcript

May 14, 2025, 4:05 PM EDT - 6 months ago

SeaStar Medical Reports First Quarter 2025 Financial Results and Provides Business Updates

May 13, 2025, 8:05 AM EDT - 6 months ago

SeaStar Medical Reaches Interim Enrollment Target for NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury

May 7, 2025, 10:00 AM EDT - 6 months ago

SeaStar Medical to Report First Quarter Financial Results on May 14, 2025

Apr 30, 2025, 8:05 AM EDT - 7 months ago

SeaStar Medical Announces CEO Interview on Benzinga All Access to Occur Today at Approximately 10:50 am Eastern Time

Apr 8, 2025, 8:05 AM EDT - 7 months ago

FDA Grants SeaStar Medical Two New Breakthrough Device Designations for SCD Therapy to Treat Systemic Inflammatory Response in Adult and Pediatric Patients Undergoing Cardiac Surgery

Mar 27, 2025, 4:05 PM EDT - 8 months ago

SeaStar Medical Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 24, 2025, 5:30 PM EDT - 8 months ago

SeaStar Medical to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025

Mar 18, 2025, 8:45 AM EDT - 8 months ago

NKF Honors SeaStar Medical, with 2025 Corporate Innovator Award

Feb 3, 2025, 4:05 PM EST - 10 months ago

SeaStar Medical Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market

Jan 22, 2025, 7:30 AM EST - 10 months ago

SeaStar Medical Activates 15th Site for its Adult Acute Kidney Injury Pivotal Trial

Jan 13, 2025, 8:30 AM EST - 10 months ago

FDA Approves Feasibility Study with SeaStar Medical's Selective Cytopheretic Device in Adults with Cardiorenal Syndrome

Jan 8, 2025, 8:30 AM EST - 11 months ago

SeaStar Medical Begins Shipping QUELIMMUNE to a Fourth Hospital Customer

Dec 23, 2024, 7:00 AM EST - 11 months ago

SeaStar Medical Activates 14th Hospital for its Adult AKI Pivotal Trial

Dec 11, 2024, 6:30 AM EST - 1 year ago

SeaStar Medical Projects Multibillion-Dollar Market Potential for its Selective Cytopheretic Device in Initial Target Indications

Dec 4, 2024, 8:30 AM EST - 1 year ago

SeaStar Medical to Hold Business Update Conference Call on December 11, 2024

Nov 26, 2024, 8:00 AM EST - 1 year ago

SeaStar Medical to Present at Noble Capital Markets' NobleCon20 on December 4, 2024

Nov 22, 2024, 8:30 AM EST - 1 year ago

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Support SeaStar Medical's Proposals to Ratify the Issuance of Shares and to Reduce the Number of Authorized Shares

Nov 15, 2024, 8:30 AM EST - 1 year ago

SeaStar Medical Reaches Milestone of 100th QUELIMMUNE Commercial Device as Shipments Begin to its Third Hospital Customer

Nov 13, 2024, 5:05 PM EST - 1 year ago

SeaStar Medical Reports Third Quarter 2024 Financial Results and Provides a Business Update

Nov 1, 2024, 8:30 AM EDT - 1 year ago

Record Monthly Enrollment Achieved in SeaStar Medical's Pivotal Adult AKI Trial

Oct 31, 2024, 8:30 AM EDT - 1 year ago

SeaStar Medical Adds Second Hospital Customer for QUELIMMUNE

Oct 25, 2024, 11:32 AM EDT - 1 year ago

Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical's QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024 - Update

Oct 25, 2024, 8:30 AM EDT - 1 year ago

Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical's QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024

Oct 22, 2024, 8:30 AM EDT - 1 year ago

SeaStar Medical to Distribute QUELIMMUNE Directly to Hospital Customers

Oct 18, 2024, 8:30 AM EDT - 1 year ago

SeaStar Medical Announces that Enrollment in its Adult Acute Kidney Injury Pivotal Trial Has Exceeded the Halfway Point Toward an Interim Analysis

Oct 15, 2024, 8:30 AM EDT - 1 year ago

SeaStar Medical to Showcase New Mechanistic Data Highlighting the Immunomodulatory Effect of the Selective Cytopheretic Device in Acute Kidney Injury at ASN Kidney Week

Oct 9, 2024, 8:30 AM EDT - 1 year ago

SeaStar Medical to Present at the 2024 Maxim Healthcare Virtual Summit

Oct 8, 2024, 8:30 AM EDT - 1 year ago

SeaStar Medical Expands NEUTRALIZE-AKI Pivotal Trial Adding Two Premier Military Medical Facilities

dnwnwntlqkffjadk Nov. 15 at 3:06 AM

0 · Reply

dnwnwntlqkffjadk Nov. 15 at 3:01 AM

0 · Reply

Bobbypogo Nov. 15 at 2:21 AM

$ICU The only thing that makes sense is Fast Track K Chung has a lot of connections and is highly regarded in his field

0 · Reply

Tjcmd Nov. 15 at 2:16 AM

$ICU RS is not necessarily a death sentence…look at what happened with CDTX today! Merk buying for $221.50!!!

1 · Reply

holn1 Nov. 15 at 12:47 AM

$ICU hope everyone has a great weekend. We're cooked!

0 · Reply

Aznwactrackstar Nov. 15 at 12:39 AM

$ICU this is seriously so depressing. What a close.

1 · Reply

windswept Nov. 15 at 12:08 AM

$ICU https://x.com/drpatsoonshiong/status/1989363831882268971?s=46&t=XftF5LoFh8RT7vWzELGP1g

1 · Reply

local42r Nov. 14 at 10:55 PM

$ICU If, I mean if seastar made a proposal to the FDA to lift the restrictions, And the FDA gave them a green light, it would shoot the sp way beyond 1 dollars. Nice dream but possible.

0 · Reply

Jafo333isme Nov. 14 at 10:27 PM

0 · Reply

techjerk Nov. 14 at 9:58 PM

$ICU Phuck stocks Cheers https://www.facebook.com/100064755394296/videos/2589531644750692/

0 · Reply

none_123 Nov. 14 at 9:47 PM

$ICU

0 · Reply

none_123 Nov. 14 at 9:46 PM

$ICU $IVVD

0 · Reply

local42r Nov. 14 at 9:45 PM

$ICU Your proxy is on it's way.

0 · Reply

GetRichorDieBuyin50 Nov. 14 at 9:27 PM

$DFLI and $FEMY are primed for take off. $ICU will have its day again

0 · Reply

local42r Nov. 14 at 8:41 PM

$ICU By the time the reverse splits. It'll probably be 25 to 1. Protect your investment and Vote No. On everything.

0 · Reply

local42r Nov. 14 at 8:38 PM

$ICU don't be their fool. Every vote counts.

0 · Reply

SparkyReturns Nov. 14 at 8:13 PM

$ICU I'll keep averaging down, thanks. Not concerned. Voting yes on RS so they have it as an option. This too shall pass. I am a very patient man. Cheers!

1 · Reply

local42r Nov. 14 at 8:05 PM

$ICU this is interesting

0 · Reply

Jw242 Nov. 14 at 7:43 PM

$ICU I am going to shit in a bag and mail it to our buddy Eric.

1 · Reply

Jafo333isme Nov. 14 at 7:42 PM

$ICU Well this is fun. Why the hell dont I have an email to vote? Where are we able to do so? Do I need to alert Etrade?

1 · Reply

YandH Nov. 14 at 7:14 PM

$ICU Don’t abandon ship. Stick around. The answer is known to all. Seek and ye shall find. GLTA.

0 · Reply

Dundery Nov. 14 at 7:10 PM

$ICU I believe the company needs to offer the SCD device at a huge discount to the current PED hospitals in order to facilitate the development of the Save registry. They could easily triple the current registry in the next 5 months and change the lives of so many families. Then, submit to the FDA the results for full approval. With full approval, they will get the critical private insurers/CMS reimbursement as well as expediting future hospital onboarding. No position.

1 · Reply

Market Cap	15.69M
Revenue (ttm)	140,000.00
Net Income (ttm)	-24.83M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-17,735.71%
Debt to Equity Ratio	0.00

Volume	1,909,600
Avg Vol	2,171,304
Day's Range	N/A - N/A
Shares Out	34.10M
Stochastic %K	10%
Beta	-1.06
Analysts	Strong Sell
Price Target	$2.00